Bpifrance

Superbranche is a biotechnology company specializing in the early detection and treatment of metastases. It develops therapeutic and diagnostic applications using nanotechnological provisions, aiming to improve accessibility and enable early tumor detection.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

Novacium operates as an innovative start-up that specializes in the next generation material development.

Quandela is a company focused on advancing quantum computing technology, specifically in the realms of communication networks and optical computers. It specializes in manufacturing photonic quantum computers, which it supplies to industrial clients. A key innovation from Quandela is its single-photon source device, which integrates photonics with semiconductor quantum dots. This device enables the efficient collection of emitted single photons at high rates, significantly reducing charge noise decoherence and facilitating the emission of identical photons with high fidelity. Such capabilities are essential for the development of advanced quantum applications in communication, computation, and sensing, positioning Quandela as a pivotal player in the quantum technology landscape.

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Quandela is a company focused on advancing quantum computing technology, specifically in the realms of communication networks and optical computers. It specializes in manufacturing photonic quantum computers, which it supplies to industrial clients. A key innovation from Quandela is its single-photon source device, which integrates photonics with semiconductor quantum dots. This device enables the efficient collection of emitted single photons at high rates, significantly reducing charge noise decoherence and facilitating the emission of identical photons with high fidelity. Such capabilities are essential for the development of advanced quantum applications in communication, computation, and sensing, positioning Quandela as a pivotal player in the quantum technology landscape.

Grapheal is a Medtech startup specializing in embedded and wearable biosensors. Utilizing graphene transistors, their wireless sensors enable accurate field diagnostics and remote patient monitoring for various biomarkers and pathogens.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

NH TherAguix SAS is a clinical-stage pharmaceutical company based in Villeurbanne, France, focused on the development of nanomedicines for cancer treatment. The company specializes in creating innovative therapeutics that enhance radiotherapy for solid tumors. Its lead product, AGuIX, is a theranostic nanoparticle designed to improve the localization of tumors and optimize radiation therapy outcomes. By facilitating intravenous administration, AGuIX enables healthcare professionals to determine the best timing for irradiation, targets tumor tissues more effectively, and minimizes adverse effects on healthy tissues by reducing radiation doses. Founded in 2015, NH TherAguix is dedicated to advancing cancer treatment through its pioneering approach to combining imaging and radiotherapy.

Founded in 2014, APIX Analytics specializes in developing miniaturized multigas analyzers systems. These systems integrate silicon-based analytical chains such as sampling, gas injection, and mixture separation to enhance specificity, detection, identification, and quantification of compounds.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.